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10 Oral PresentationsPeripheral blood stem cells (PBSC) have been increasingly used
in the matched unrelated donor (MUD) transplant setting, but
the impact of CD341 cell dose on outcomes in this setting have
not been well characterized. We analyzed a consecutive case-series
of 181 patients who underwentMUD-PBSC transplantation at City
of Hope from August 2000 to December 2004. Eighty-three pa-
tients were conditioned with a full-intensity regimen (TBI-Cy:
46, TBI-VP16: 28, Bu-Cy: 9) and 98 received a reduced-intensity
regimen (Flu-Mel: 97, Flu-Bu: 1). The two-year overall survival
(OS), disease-free survival (DFS), relapse, and 100-day transplant-
related mortality (TRM) probabilities were 52%64%, 47%64%,
29%64%, and 156 3% respectively. There was a highly significant
correlation betweenCD341 cell dose infused and absolute lympho-
cyte count on day 30 post-transplant (r 5 0.378, p\ 0.0001). By
univariate analysis, a CD341 cell dose $4.2  106/kg (above the
lowest quartile: p25) was associated with significantly lower relapse
risk (HR5 0.67; p5 0.013), with a trend toward improved disease-
free survival (HR 5 0.84; p 5 0.12) but not overall survival (HR 5
0.91; p5 0.46). There was no significant association between higher
CD341 cell dose and TRM or acute/chronic GVHD. By multivar-
iate analysis, cellular composition of the PBSC grafts remained sig-
nificant in influencing transplant outcomes (Table 1). Further
subset analysis of low risk group (n 5 35) versus high-risk disease
(n5 146) showed that the CD341 dose$ p25 was significantly as-
sociated with reduced relapse in high-risk disease (p 5 0.015),
whereas the p-value was not significant in low-risk disease (p 5
0.5). Among 18 patients with an iKIRL mismatch in the GVH di-
rection, the log-rank p-value for comparing\ p25 of CD341 cell
dose versus those who received higher doses was p\ 0.0001 with
respect to time to relapse. This is in contrast with p5 0.041 among
the others. We also performed a stratified analysis in patients lack-
ing iKIRL (n 5 56) versus not (n 5 125). When stratified by
CD341 cell dose, time-to-relapse was not significant among the pa-
tients who did not lack iKIRL but was significant in patients lacking
iKIRL (p 5 0.0030). In summary, we demonstrate that the higher
CD341 cell dose reduces relapse in MUD-PBSCT, in particular,
for high-risk diseases. The data also suggest that the protective ef-
fect of higher CD341 cell dose may be linked to an NK cell-medi-
ated GVL effect.Table 1.
HR p-valuesOS
10/10 HLA match
(baseline) vs. others2.23 (95%CI: 1.46–3.43) 0.0002Lymphocyte dose in
the graft (continuous)0.20 (95%CI: 0.05–0.64) 0.005MNC dose in the
graft: p25 (baseline)
vs. others1.34 (95%CI: 1.01–1.82) 0.04DFS
10/10 HLA match
(baseline) vs. others1.91 (95%CI: 1.28–2.87) 0.001Lymphocyte dose in
the graft (continuous)0.35 (95%CI: 0.14–0.81) 0.01Good risk disease
(baseline) vs. others1.73 (95%CI: 1.01–3.17) 0.04Relapse
CD341 quartile: p25
(baseline) vs. others0.64 (95%CI: 0.47–0.88) 0.01Recipient age
(continuous)1.02 (95%CI: 1.00–1.05) 0.02TRM
10/10 HLA match
(baseline) vs. others2.46 (95%CI: 1.44–4.30) 0.001Full-intensity
(baseline) vs.
reduced-intensity
conditioning1.76 (95%CI: 1.03–3.10) 0.04MNC: mononuclear cell.21
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Naturally occurring regulatory T cells (Treg) may limit or pre-
vent the immune mediated morbidity associated with allogeneic
transplants. The administration of Treg along with specified doses
of conventional T cells (Tcon) has been proposed as an alternative
to current T cell reduction strategies. This approach may provide
patients with immune protection and graft-versus-tumor activity
during post-transplant immune reconstitution while minimizing
the risk of severe graft-versus-host responses when the donor and
recipient are mismatched.
In order to establish the optimal dose of Treg to be administered
with Tcon, highly purified Treg are required. Isolation of Tregs for
clinical application is complicated by the lack of an exclusive surface
marker suitable for selection and the relatively rare representation
(\1%) of the cells in peripheral blood. Treg are characterized by
surface expression of CD4, CD25, CTLA-4, and GITR among
other markers and by intracellular expression of the transcriptional
factor FoxP3.
We conducted a feasibility study of a cell selection strategy that
combines immunomagnetic enrichment of CD251 cells with high
flow cytometric speed cell sorting of CD41CD25brightCD127dim
cells. System operations took into consideration selection effi-
ciency, effect on cell viability and functionality as well as the
risk of contamination both from external sources and product
cross-contamination. Using this approach, we have obtained cells
that are .95% FoxP31 by intracellular staining and showing ti-
tratable suppression in MLR assays. Recovery of the target cell
population on the Influx cell sorter was .90% at 20,000 events
per second and without detectable microbial contamination. In ad-
dition, more than 100  106 FoxP31 Tregs were routinely ob-
tained from individual G-CSF mobilized donor apheresis
collections.GVH/GVL22
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TRO STIMULATION OF NAI¨VE T CELLS
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Allogeneic hematopoietic stem cell transplantation (HCT) is cu-
rative for many patients with leukemia in part due to a graft versus
leukemia (GVL) effect mediated by donor T cells specific for recip-
ient minor histocompatibility antigens (miH) on leukemic cells.
Unfortunately, the GVL effect fails to completely eradicate leu-
kemia in some patients, and additional strategies for preventing
and treating post HCT relapse are required. Immunotherapy tar-
geting miH selectively expressed on hematopoietic cells, includ-
ing leukemia, could be used to augment the GVL effect
without inducing GVHD but too few human miH have been mo-
lecularly characterized for this approach to be broadly applied.
The identification of additional leukemia associated miH is essen-
tial. We developed a new strategy that employs primary in vitro
stimulation of donor naı¨ve CD81 T cells (TN) with recipient
APC in microcultures, allowing generation of a broad repertoire
of miH specific CTL for gene discovery. Using this approach,
.100 miH specific CD81 CTL lines were derived from 19
HLA identical sibling recipient-donor pairs and further charac-
terized using a panel of target cells from unrelated individuals
to determine the HLA restricting allele and population frequency
of the miH. CTL directed against multiple distinct miH were
